28272227|t|Effects of pulmonary static inflation with 50% xenon on oxygen impairment during cardiopulmonary bypass for stanford type A acute aortic dissection: A pilot study
28272227|a|The goal of this study was to investigate the effects of pulmonary static inflation with 50% xenon on postoperative oxygen impairment during cardiopulmonary bypass (CPB) for Stanford type A acute aortic dissection (AAD). This prospective single-center nonrandomized controlled clinical trial included 100 adult patients undergoing surgery for Stanford type A AAD at an academic hospital in China. Fifty subjects underwent pulmonary static inflation with 50% oxygen from January 2013 to January 2014, and 50 underwent inflation with 50% xenon from January 2014 to December 2014. During CPB, the lungs were inflated with either 50% xenon (xenon group) or 50% oxygen (control group) to maintain an airway pressure of 5 cm H2O. The primary outcome was oxygenation index (OI) value after intubation, and 10 minutes and 6 hours after the operation. The second outcome was cytokine and reactive oxygen species levels after intubation and 10 minutes, 6 hours, and 24 hours after the operation. Patients treated with xenon had lower OI levels compared to the control group before surgery (P = 0.002); however, there was no difference in postoperative values between the 2 groups. Following surgery, mean maximal OI values decreased by 18.8% and 33.8%, respectively, in the xenon and control groups. After surgery, the levels of interleukin-6 (IL-6), tumor necrosis factor alpha, and thromboxane B2 decreased by 23.5%, 9.1%, and 30.2%, respectively, in the xenon group, but increased by 10.8%, 26.2%, and 26.4%, respectively, in the control group. Moreover, IL-10 levels increased by 28% in the xenon group and decreased by 7.5% in the control group. There were significant time and treatment - time interaction effects on methane dicarboxylic aldehyde (P = 0.000 and P = 0.050, respectively) and myeloperoxidase (P = 0.000 and P = 0.001 in xenon and control groups, respectively). There was no difference in hospital mortality and 1-year survival rate between the 2 groups. Pulmonary static inflation with 50% xenon during CPB could attenuate OI decreases at the end of surgery for Stanford type A AAD. Thus, xenon may function by triggering anti-inflammatory responses and suppressing pro-inflammatory and oxidative effects.
28272227	0	10	Effects of	T080	C1704420
28272227	11	20	pulmonary	T023	C0024109
28272227	21	37	static inflation	T061	C1283105
28272227	47	52	xenon	T121,T196	C0043339
28272227	56	62	oxygen	T121,T123,T196	C0030054
28272227	63	73	impairment	T169	C0221099
28272227	81	103	cardiopulmonary bypass	T061	C0007202
28272227	108	147	stanford type A acute aortic dissection	T047	C0241868
28272227	151	162	pilot study	T062	C0031928
28272227	167	171	goal	T170	C0018017
28272227	180	185	study	T062	C2603343
28272227	209	219	effects of	T080	C1704420
28272227	220	229	pulmonary	T023	C0024109
28272227	230	246	static inflation	T061	C1283105
28272227	256	261	xenon	T121,T196	C0043339
28272227	265	278	postoperative	T079	C0032790
28272227	279	285	oxygen	T121,T123,T196	C0030054
28272227	286	296	impairment	T169	C0221099
28272227	304	326	cardiopulmonary bypass	T061	C0007202
28272227	328	331	CPB	T061	C0007202
28272227	337	376	Stanford type A acute aortic dissection	T047	C0241868
28272227	378	381	AAD	T047	C0241868
28272227	401	454	single-center nonrandomized controlled clinical trial	T062	C2985410
28272227	468	473	adult	T100	C0001675
28272227	474	482	patients	T101	C0030705
28272227	494	501	surgery	T061	C0543467
28272227	506	525	Stanford type A AAD	T047	C0241868
28272227	532	549	academic hospital	T073,T093	C0000872
28272227	553	558	China	T083	C0008115
28272227	585	594	pulmonary	T023	C0024109
28272227	595	611	static inflation	T061	C1283105
28272227	621	627	oxygen	T121,T123,T196	C0030054
28272227	633	640	January	T080	C3829466
28272227	649	656	January	T080	C3829466
28272227	680	689	inflation	T061	C1283105
28272227	699	704	xenon	T121,T196	C0043339
28272227	710	717	January	T080	C3829466
28272227	726	734	December	T080	C3830550
28272227	748	751	CPB	T061	C0007202
28272227	757	762	lungs	T023	C0024109
28272227	768	776	inflated	T061	C1283105
28272227	793	798	xenon	T121,T196	C0043339
28272227	800	811	xenon group	UnknownType	C0681860
28272227	820	826	oxygen	T121,T123,T196	C0030054
28272227	828	841	control group	T096	C0009932
28272227	858	873	airway pressure	T201	C0428719
28272227	891	906	primary outcome	T169	C1274040
28272227	911	928	oxygenation index	T059	C1278185
28272227	930	932	OI	T059	C1278185
28272227	934	939	value	T081	C1522609
28272227	946	956	intubation	T061	C0021925
28272227	965	972	minutes	T079	C0439232
28272227	979	984	hours	T079	C0439227
28272227	995	1004	operation	T061	C0543467
28272227	1010	1024	second outcome	T169	C1274040
28272227	1029	1037	cytokine	T116,T129	C0079189
28272227	1042	1065	reactive oxygen species	T123,T196	C0162772
28272227	1066	1072	levels	T080	C0441889
28272227	1079	1089	intubation	T061	C0021925
28272227	1097	1104	minutes	T079	C0439232
28272227	1108	1113	hours	T079	C0439227
28272227	1122	1127	hours	T079	C0439227
28272227	1138	1147	operation	T061	C0543467
28272227	1149	1157	Patients	T101	C0030705
28272227	1171	1176	xenon	T121,T196	C0043339
28272227	1187	1189	OI	T059	C1278185
28272227	1190	1196	levels	T080	C0441889
28272227	1213	1226	control group	T096	C0009932
28272227	1234	1241	surgery	T061	C0543467
28272227	1274	1287	no difference	T033	C3842396
28272227	1291	1304	postoperative	T079	C0032790
28272227	1305	1311	values	T081	C1522609
28272227	1326	1332	groups	UnknownType	C0681860
28272227	1344	1351	surgery	T061	C0543467
28272227	1353	1357	mean	T081	C0444504
28272227	1358	1365	maximal	T081	C0806909
28272227	1366	1368	OI	T059	C1278185
28272227	1369	1375	values	T081	C1522609
28272227	1376	1385	decreased	T081	C0205216
28272227	1427	1432	xenon	UnknownType	C0681860
28272227	1437	1451	control groups	T096	C0009932
28272227	1459	1466	surgery	T061	C0543467
28272227	1472	1478	levels	T080	C0441889
28272227	1482	1495	interleukin-6	T116,T129	C0021760
28272227	1497	1501	IL-6	T116,T129	C0021760
28272227	1504	1531	tumor necrosis factor alpha	T116,T129	C1456820
28272227	1537	1551	thromboxane B2	T109,T123	C0040059
28272227	1552	1561	decreased	T081	C0205216
28272227	1610	1621	xenon group	UnknownType	C0681860
28272227	1627	1636	increased	T081	C0205217
28272227	1686	1699	control group	T096	C0009932
28272227	1711	1716	IL-10	T116,T129	C0085295
28272227	1717	1723	levels	T080	C0441889
28272227	1724	1733	increased	T081	C0205217
28272227	1748	1759	xenon group	UnknownType	C0681860
28272227	1764	1773	decreased	T081	C0205216
28272227	1789	1802	control group	T096	C0009932
28272227	1827	1831	time	T079	C0040223
28272227	1836	1845	treatment	T061	C0087111
28272227	1848	1852	time	T079	C0040223
28272227	1853	1864	interaction	T169	C1704675
28272227	1865	1872	effects	T080	C1280500
28272227	1876	1905	methane dicarboxylic aldehyde	T123	C0574031
28272227	1950	1965	myeloperoxidase	T116,T126	C0027021
28272227	1994	1999	xenon	UnknownType	C0681860
28272227	2004	2018	control groups	T096	C0009932
28272227	2045	2058	no difference	T033	C3842396
28272227	2062	2080	hospital mortality	T080	C0085556
28272227	2092	2105	survival rate	T081	C0038954
28272227	2120	2126	groups	UnknownType	C0681860
28272227	2128	2137	Pulmonary	T023	C0024109
28272227	2138	2154	static inflation	T061	C1283105
28272227	2164	2169	xenon	T121,T196	C0043339
28272227	2177	2180	CPB	T061	C0007202
28272227	2197	2199	OI	T059	C1278185
28272227	2200	2209	decreases	T081	C0547047
28272227	2224	2231	surgery	T061	C0543467
28272227	2236	2255	Stanford type A AAD	T047	C0241868
28272227	2263	2268	xenon	T121,T196	C0043339
28272227	2273	2281	function	T169	C0542341
28272227	2296	2323	anti-inflammatory responses	T080	C1515999
28272227	2328	2339	suppressing	T169	C1260953
28272227	2340	2356	pro-inflammatory	T169	C0333348
28272227	2361	2370	oxidative	T169	C0311404
28272227	2371	2378	effects	T080	C1280500